drug · small molecule
ponesimod
Marketedupdated 3mo agoby $VNDA Vanda Pharmaceuticals Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for relapsing-remitting multiple sclerosis and multiple sclerosis and 3 investigational indications.
indications
investigational
IBD (Crohn's + UC)Psoriasis
targets
Sphingosine 1-phosphate receptor 1
all catalysts(0)
nothing on the calendar yet
Trials studying ponesimod
- phase3Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
- —A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- phase3Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
- phase3Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
- phase1A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State
- phase1A Study of Ponesimod in Healthy Adult Participants
- phase2Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
- phase3Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 16, 2029
~3.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (50)
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Oct 10, 2042method-of-use (U-3891)US 11951097
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 10220023
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- Dec 10, 2035method-of-use (U-3103)US 12336980
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- May 6, 2032compositionUS 9062014
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
- Nov 16, 2029compositionUS RE437283.2y
FDA exclusivities (10)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
- Mar 18, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that